TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31815770
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion nanotechnology monitoring system with fuzzy logic alarm algorithm
Study: 24805894
Drug: Cognitive Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Symptom Management and Rehabilitation Therapy (CogSMART)
Study: 30056389
Drug: Routine aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine aspirin 75 mg from 11 until 36 weeks
Study: 26593941
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of C. forskohlii extract, twice daily for 12 weeks
Study: 8777828
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (as required)
Study: 30114246
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of glargine (1.6 U/kg body weight)
Study: 31058615
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control - no bleaching treatment
Study: 21557207
Drug: Sivelestat sodium
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sivelestat sodium hydrate (SSH) administered intravenously for 7 days
Study: 348379
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), 750 mg 4 times daily
Study: 30937940
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg oral dose
Study: 30401602
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate solution (OCS) administration
Study: 31538430
Drug: Short-term exposure
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term exposure to PM2.5 exceeding 50 µg/m3
Study: 31538430
Drug: Very short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Very short-term exposure to PM2.5 exceeding 50 µg/m3 for 2 hours
Study: 30507875
Drug: Acemetacin (5 mg/kg/d)
Normalized name: acemetacin
DrugBank: Acemetacin (DB13783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (5 mg/kg/d)
Study: 26765317
Drug: High analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: High analgesic consumption
Study: 30499511
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab, 0.05 ml, administered twice with one-month interval.
Study: 27442000
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of betamethasone and lidocaine into the lumbar facet joint
Study: 2287055
Drug: Conventional cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional cefaclor preparation (CCL) (500 mg three times daily for 5 days)
Study: 18083783
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Insulin
Study: 14500805
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Parathyroid hormone + Alendronate)
Study: 6140541
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 2 g orally in divided doses
Study: 8872689
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rocuronium 0.6 mg/kg and mivacurium 0.15 mg/kg
Study: 6472796
Drug: Solcoseryl Eye-Gel
Normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoseryl Eye-Gel
Study: 6365147
Drug: PUVA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA and etretinate (0.75 mg/kg)
Study: 15631537
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg/day
Study: 31119456
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin (control)
Study: 2705633
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg daily
Study: 20673678
Drug: BNP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided therapy
Study: 1098495
Drug: Oral rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rifampin (600 mg daily)
Study: 29771066
Drug: Intratympanic budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intratympanic budesonide injection
Study: 19342396
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg daily
Study: 2576322
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment
Study: 29343131
Drug: Plecanatide 3
Normalized name: plecanatide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide 3 mg
Study: 26315980
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic treatment
Study: 29545635
Drug: Plecanatide 3
Normalized name: plecanatide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide 3 mg and 6 mg
Study: 19094430
Drug: Thiamine pyrophosphate
Normalized name: Thiamine pyrophosphate
DrugBank: Cocarboxylase (DB01987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine pyrophosphate (TPP) 1 mg/kg
Study: 31606460
Drug: Pooled human
Normalized name: Coagulation Factor X (Pooled Human Plasma)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled human immune globulin-eye drops (IVIG 4 mg/mL) twice a day for 8 weeks
Study: 28770947
Drug: Single-agent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent or combination anti-epileptic therapy with oxcarbazepine and sodium valproate
Study: 3908603
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine treatment before suture
Study: 31684921
Drug: In-clinic physical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic physical therapy intervention including manual therapy, stretching, strengthening, and neuromuscular functional training.
Study: 26059526
Drug: Desmopressin tablets
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablets for 6 months
Study: 1763561
Drug: Misoprostol (MS)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (MS) therapy (400 micrograms bid)
Study: 21385988
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (active control)
Study: 26920602
Drug: Interrupted novel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interrupted novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Study: 17403578
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of ET-1 (concentrations ranging from 10(‐10) to 10(‐6)M)
Study: 17197012
Drug: Intravaginal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal radiation therapy (IVRT)
Study: 30181338
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin (10 IU in 1 mL)
Study: 12920409
Drug: Rapid initial
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid initial dose escalation (RIDE) of up to 40 mg of oral olanzapine on days 1 and 2, up to 30 mg on days 3 and 4, and 5 to 20 mg thereafter
Study: 9292632
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No capsule administered on days 1 and 9
Study: 6297363
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human beta‐EP by constant rate IV infusion
Study: 17102001
Drug: Timolol alone
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol alone dosed twice daily
Study: 28241356
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel for 1 year
Study: 14741172
Drug: Vaccine consisting
Normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine consisting of recombinant baculovirus-derived KSA formulated with monophosphoryl lipid A (MPL) in liposomes and emulsified in mineral oil
Study: 14741172
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with co-administration of human recombinant GM-CSF (rGM-CSF)
Study: 14741172
Drug: Vaccine without
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine without GM-CSF
Study: 22324448
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation
Study: 24010771
Drug: Whole-brain irradiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain irradiation (WBI) with concomitant chloroquine (CLQ) 150 mg for 4 weeks
Study: 7986837
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT technique, CM volume 150 ml of Ultravist 300 (30 ml at a flow rate of 1.5 ml/s, remaining 120 ml at 0.5 ml/s)
Study: 20862715
Drug: Intravenous Salvia
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Salvia miltiorrhiza after surgery for 3 days
Study: 29804469
Drug: Zinc Gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc Gluconate 233 mg/day plus vitamin E 400 IU/day for 6 weeks
Study: 3989142
Drug: PEG-modified ragweed
Normalized name: Co-ArgI-PEG modified human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-modified ragweed extract (10 weekly injections for group 1, 6 injections for group 2, followed by 10 injections before the second season)
Study: 27182022
Drug: Overcoming Compassion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overcoming Compassion Fatigue Program (5 weekly 80-minute sessions)
Study: 25145986
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite sublingual immunotherapy (SLIT) with Dermatophagoides farinae extracts for 52 weeks, combined with standard pharmacotherapy.
Study: 20110015
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (generic and branded)
Study: 10419912
Drug: Omeprazole therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole therapy
Study: 11762805
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (ciprofloxacin plus roxithromycin)
Study: 29605753
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group 1 - midwifery intervention involving oral health education, screening and referrals to existing dental pathways
Study: 20735290
Drug: Eltrombopag 100
Normalized name: eltrombopag 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 100 mg
Study: 14646710
Drug: Highly cross-linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly cross-linked polyethylene (absorbed dose, 95 kGy)
Study: 14646710
Drug: Conventional gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gamma irradiated polyethylene (absorbed dose, 25-40 kGy)
Study: 1674677
Drug: Vecuronium (V)
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium (V) 0.1 mg.kg‐1
Study: 9659700
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Sulprostongel (Nalador)
Study: 1743318
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (400 mg pessary)
Study: 31069442
Drug: Low baseline
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low baseline 25OHD < 25 nmol/L
Study: 28990437
Drug: Injection volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection volume of 2250 µL
Study: 12707157
Drug: Bupivacaine 6
Normalized name: BUPivacaine 660 MG in 5 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 6 mg with saline (Control Group B)
Study: 4684623
Drug: Marijuana cigarette
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana cigarette containing less than 0.01 mg Delta(9)-THC
Study: 4684623
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of marijuana
Study: 25240806
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for women
Study: 19148110
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous digoxin immune Fab (DIF)
Study: 30971278
Drug: BCc1 nanomedicine
Normalized name: BCc1
DrugBank: BCc1 (DB16504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCc1 nanomedicine (3000 mg for metastatic, 1500 mg for non-metastatic)
Study: 27543500
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of calcium as citrate
Study: 10710049
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) pantoprazole (40 mg and 20 mg)
Study: 11104314
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Comb) group (medicated)
Study: 30002864
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab
Study: 17641254
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 mg/day
Study: 23859414
Drug: Sauna treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sauna treatment
Study: 21932426
Drug: Personalized peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized peptide vaccine (PPV)
Study: 26114410
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV)
Study: 24046309
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oseltamivir twice daily for 5 days
Study: 29513931
Drug: AMG 557
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 557 210 mg
Study: 30660342
Drug: Intravenous NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous NSAIDs
Study: 16769748
Drug: Clomifene citrate
Normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomifene citrate plus metformin
Study: 14581795
Drug: Glutamine-supplemented parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented parenteral nutrition (n = 17)
Study: 12182757
Drug: 50 micro
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micro g octreotide
Study: 24869609
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion preoperatively and throughout surgery
Study: 19606048
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (equal volume to morphine group)
Study: 3541091
Drug: sobrerol 300
Normalized name: sobrerol
DrugBank: Sobrerol (DB13315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sobrerol 300 mg b.i.d. for 3 months
Study: 28509812
Drug: Ospemifene 60
Normalized name: ospemifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ospemifene 60 mg
Study: 28289237
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy (clopidogrel-aspirin)
Study: 30610279
Drug: R-CHOP plus
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP plus 8 doses of rituximab
Study: 28926353
Drug: Lacosamide 800
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide 800 mg
Study: 6509876
Drug: Extended phenytoin
Normalized name: Extended Phenytoin Sodium Capsules
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended phenytoin sodium capsules
Study: 15174791
Drug: Filtered infusions
Normalized name: FILTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered infusions via a central catheter
Study: 29171818
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8)
Study: 30404123
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections (palpation-guided)
Study: 24135139
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAAs) 20 g twice daily for 1 week before and 2 weeks after TKA
Study: 10365809
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (23-25 mg x kg(‐1) x day(‐1))
Study: 22215918
Drug: Stimulus Control
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus Control Therapy (SCT)
Study: 16104447
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy (CPT) after thoracoscopic surgery
Study: 30552176
Drug: Lutikizumab 200
Normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks
Study: 3895410
Drug: Emepronium carrageenate
Normalized name: emepronium carrageenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium carrageenate (EC) 500 mg
Study: 21783298
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of meloxicam IM
Study: 1972557
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (800 micrograms)
Study: 11293210
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination
Study: 11865830
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 1800 mg/day
Study: 24602844
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral treatment
Study: 1452593
Drug: Distraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction therapy using videos during burn dressing changes
Study: 6711270
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 1% mepivacaine with adrenaline 1:200,000
Study: 29855172
Drug: ABT-122 60
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 60 mg every other week
Study: 7197091
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (gestagen therapy)
Study: 22634446
Drug: VLP immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLP immunotherapy in Wenzhou
Study: 19895362
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with birch pollen allergen extract
Study: 12749125
Drug: PGE1 cream
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 cream